Rotigotine for the treatment of Parkinson's disease

John C. Morgan, Kapil D. Sethi

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Dopaminergic therapies, including levodopa and dopamine agonists, are the mainstays of therapy in Parkinson's disease. With the exception of the injectable short-acting dopamine agonist apomorphine, there is no other widely available non-oral dopaminergic therapy. Rotigotine is a lipid-soluble, non-ergot, D3, D2, D1 dopamine receptor agonist that has demonstrated efficacy as an alternative therapeutic option in both early and advanced Parkinson's disease. More importantly, it is uniquely formulated as a transdermal patch delivery system allowing for continuous, once-daily administration and better patient compliance. Preclinical and clinical trials have shown rotigotine to be a well-tolerated and effective treatment for early-stage Parkinson's disease. Rotigotine has also shown promise as adjunctive therapy with levodopa for the treatment of advanced Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)1275-1282
Number of pages8
JournalExpert Review of Neurotherapeutics
Issue number9
StatePublished - Sep 1 2006


  • Continuous dopaminergic stimulation
  • Dopamine agonist
  • N-0437
  • N-0923
  • Parkinson's disease
  • Rotigotine
  • Transdermal patch

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Rotigotine for the treatment of Parkinson's disease'. Together they form a unique fingerprint.

Cite this